x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0231312
| Product Information | |
|---|---|
| CAS No. | 612847-09-3 |
| Synonyms | Akt Inhibitor VIII |
| Formula | C34H29N7O |
| Molecular Weight | 551.64 |
| SMILES | O=C1NC2=C(C=CC=C2)N1C3CCN(CC3)CC4=CC=C(C=C4)C5=C(N=C6C=C7[NH]C=NC7=CC6=N5)C8=CC=CC=C8 |
| Product Description | Akti-1/2 is a highly selective Akt1/Akt2 inhibitor with IC50 of 58 nM/210 nM, respectively, about 36-fold selectivity for Akt1 over Akt3. |
| Format & Storage | |
|---|---|
| Purity | > 99% |
| Shipping | Shipped on dry ice. |
| Storage | Powder: -20 °C, 3 years; 4 °C, 2 years In solvent: -80 °C, 6 months; -20 °C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
